[go: up one dir, main page]

WO2015108577A1 - Dérivés de diphénylurée servant de modulateurs des récepteurs des peptides formylés - Google Patents

Dérivés de diphénylurée servant de modulateurs des récepteurs des peptides formylés Download PDF

Info

Publication number
WO2015108577A1
WO2015108577A1 PCT/US2014/059765 US2014059765W WO2015108577A1 WO 2015108577 A1 WO2015108577 A1 WO 2015108577A1 US 2014059765 W US2014059765 W US 2014059765W WO 2015108577 A1 WO2015108577 A1 WO 2015108577A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
alkyl
hydrogen
oxadiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/059765
Other languages
English (en)
Inventor
Ling Li
Janet A. Takeuchi
Ken Chow
Michael E. Garst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of WO2015108577A1 publication Critical patent/WO2015108577A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings
    • C07F9/65306—Five-membered rings containing two nitrogen atoms
    • C07F9/65312—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 2

Definitions

  • the present invention relates to 1 ,3,4-oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1 -phosphate receptors.
  • the invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with sphingosine-1 -phosphate (S1 P) receptor modulation.
  • Sphingosine-1 phosphate is stored in relatively high concentrations in human platelets, which lack the enzymes responsible for its catabolism, and it is released into the blood stream upon activation of physiological stimuli, such as growth factors, cytokines, and receptor agonists and antigens. It may also have a critical role in platelet aggregation and thrombosis and could aggravate cardiovascular diseases.
  • physiological stimuli such as growth factors, cytokines, and receptor agonists and antigens. It may also have a critical role in platelet aggregation and thrombosis and could aggravate cardiovascular diseases.
  • the relatively high concentration of the metabolite in high-density lipoproteins (HDL) may have beneficial implications for atherogenesis.
  • sphingosine-1 -phosphate together with other lysolipids such as sphingosylphosphorylcholine and lysosulfatide, are responsible for the beneficial clinical effects of HDL by stimulating the production of the potent antiatherogenic signaling molecule nitric oxide by the vascular endothelium.
  • lysophosphatidic acid it is a marker for certain types of cancer, and there is evidence that its role in cell division or proliferation may have an influence on the development of cancers.
  • modulator includes but is not limited to: receptor agonist, antagonist, inverse agonist, inverse antagonist, partial agonist, partial antagonist.
  • This invention describes compounds of Formula I, which have sphingosine-1 - phosphate receptor biological activity.
  • the compounds in accordance with the present invention are thus of use in medicine, for example in the treatment of humans with diseases and conditions that are alleviated by S1 P modulation.
  • the invention provides a compound having Formula I or a
  • R 1 is substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, substituted or unsubstituted C 5 -8 cycloalkyl, substituted or unsubstituted C 5 -8 cycloalkenyl;
  • R 2 is substituted or unsubstituted Ci -8 alkyl
  • R 3 is hydrogen, halogen, substituted or unsubstituted C -6 alkyl, C(0)R 10 or hydroxyl
  • R 4 is hydrogen, halogen, substituted or unsubstituted C -6 alkyl, C(0)R 10 or hydroxyl
  • R 5 is hydrogen, halogen, substituted or unsubstituted Ci -6 alkyl, C(0)R 10 or hydroxyl
  • R 6 is hydrogen, halogen, substituted or unsubstituted C -6 alkyl, C(0)R 10 or hydroxyl
  • R 7 is hydrogen, substituted or unsubstituted Ci -6 alkyl
  • R 8 is hydrogen, substituted or unsubstituted Ci -6 alkyl
  • R 9 is OPO3H2, carboxylic acid, P0 3 H 2 , -P(0)MeOH, -P(0)(H)OH or OR 11 ;
  • R 10 is OR 9 , substituted or unsubstituted Ci -6 alkyl
  • R 11 is hydrogen, substituted or unsubstituted C -6 alkyl
  • a is 1 , 2 or 3;
  • b is 1 , 2 or 3.
  • the invention provides a compound having Formula I, wherein:
  • R 1 is substituted or unsubstituted aryl
  • R 2 is substituted or unsubstituted Ci -8 alkyl
  • R 3 is hydrogen, halogen, substituted or unsubstituted C -6 alkyl, C(0)R 10 or hydroxyl;
  • R 4 is hydrogen, halogen, substituted or unsubstituted C -6 alkyl, C(0)R 10 or hydroxyl
  • R 5 is hydrogen, halogen, substituted or unsubstituted Ci -6 alkyl, C(0)R 10 or hydroxyl
  • R 6 is hydrogen, halogen, substituted or unsubstituted C -6 alkyl, C(0)R 10 or hydroxyl;
  • R 7 is hydrogen, substituted or unsubstituted Ci -6 alkyl
  • R 8 is hydrogen, substituted or unsubstituted Ci -6 alkyl
  • R 9 is OPO3H2, carboxylic acid, P0 3 H 2 , -P(0)MeOH, -P(0)(H)OH or OR 11 ;
  • R 10 is OR 9 , substituted or unsubstituted Ci -6 alkyl
  • R 11 is hydrogen, substituted or unsubstituted C -6 alkyl
  • a is 1 , 2 or 3;
  • b is 1 , 2 or 3.
  • the invention provides a compound having Formula I, wherein:
  • R 1 is substituted or unsubstituted aryl
  • R 2 is substituted or unsubstituted Ci -8 alkyl
  • R 3 is hydrogen, halogen, substituted or unsubstituted Ci .6 alkyl, C(0)R 10 or hydroxyl;
  • R 4 is hydrogen, halogen, substituted or unsubstituted Ci .6 alkyl, C(0)R 10 or hydroxyl
  • R 5 is hydrogen, halogen, substituted or unsubstituted Ci -6 alkyl, C(0)R 10 or hydroxyl
  • R 6 is hydrogen, halogen, substituted or unsubstituted Ci 6 alkyl, C(0)R 10 or hydroxyl;
  • R 7 is hydrogen, substituted or unsubstituted Ci -6 alkyl
  • R 8 is hydrogen, substituted or unsubstituted C1-6 alkyl
  • R 9 is carboxylic acid
  • R 10 is OR 9 , substituted or unsubstituted C -6 alkyl
  • R 11 is hydrogen, substituted or unsubstituted C -6 alkyl
  • a is 1 , 2 or 3;
  • b is 1 , 2 or 3.
  • the invention provides a compound having Formula I, wherein:
  • R 1 is substituted or unsubstituted aryl
  • R 2 is substituted or unsubstituted Ci -8 alkyl
  • R 3 is hydrogen, halogen, substituted or unsubstituted C -6 alkyl, C(0)R 10 or hydroxyl
  • R 4 is hydrogen, halogen, substituted or unsubstituted C -6 alkyl, C(0)R 10 or hydroxyl
  • R 5 is hydrogen, halogen, substituted or unsubstituted Ci-e alkyl, C(0)R 10 or hydroxyl;
  • R 6 is hydrogen, halogen, substituted or unsubstituted C -6 alkyl, C(0)R 10 or hydroxyl;
  • R 7 is hydrogen, substituted or unsubstituted Ci -6 alkyl
  • R 8 is hydrogen, substituted or unsubstituted Ci -6 alkyl
  • R 9 is P0 3 H 2 ;
  • R 10 is OR 9 , substituted or unsubstituted C -6 alkyl
  • R 11 is hydrogen, substituted or unsubstituted C -6 alkyl
  • a is 1 , 2 or 3;
  • b is 1 , 2 or 3.
  • the invention provides a compound having Formula I, wherein:
  • R 1 is substituted or unsubstituted aryl
  • R 2 is substituted or unsubstituted Ci -8 alkyl
  • R 3 is hydrogen
  • R 4 is hydrogen
  • R 5 is hydrogen
  • R 6 is hydrogen
  • R 7 is hydrogen
  • R 8 is hydrogen
  • R 9 is carboxylic acid or P0 3 H 2 ;
  • a 1 ;
  • b 2 or 3.
  • the invention provides a compound having Formula I, wherein: R 1 is substituted or unsubstituted aryl;
  • R 2 is methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, iso- pentyl, neo-pentyl, hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3- dimethylbutyl;
  • R 3 is hydrogen
  • R 4 is hydrogen
  • R 5 is hydrogen
  • R 6 is hydrogen
  • R 7 is hydrogen
  • R 8 is hydrogen
  • R 9 is carboxylic acid or PO3H2;
  • a 1 ;
  • the invention provides a compound having Formula II or a pharmaceutically acceptable salt thereof or enantiomers, diastereoisomers, tautomers, zwitterions and pharmaceutically acceptable salts thereof:
  • R 1 is substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, substituted or unsubstituted C5-8 cycloalkyl, substituted or unsubstituted C5-8 cycloalkenyl;
  • R 2 is substituted or unsubstituted Ci-s alkyl
  • R 3 is hydrogen, halogen, substituted or unsubstituted C -6 alkyl, C(0)R 8 or hydroxyl
  • R 4 is hydrogen, halogen, substituted or unsubstituted C -6 alkyl, C(0)R 8 or hydroxyl
  • R 5 is hydrogen, halogen, substituted or unsubstituted Ci -6 alkyl, C(0)R 8 or hydroxyl
  • R 6 is hydrogen, halogen, substituted or unsubstituted C -6 alkyl, C(0)R 8 or hydroxyl
  • R 7 is hydrogen, substituted or unsubstituted Ci -6 alkyl
  • R 8 is OR 9 , substituted or unsubstituted Ci -6 alkyl
  • R 9 is hydrogen, substituted or unsubstituted Ci -6 alkyl
  • a is 1 , 2 or 3.
  • the invention provides a compound having Formula II, wherein:
  • R 1 is substituted or unsubstituted aryl
  • R 2 is substituted or unsubstituted Ci -8 alkyl
  • R 3 is hydrogen, halogen, substituted or unsubstituted C -6 alkyl, C(0)R 8 or hydroxyl
  • R 4 is hydrogen, halogen, substituted or unsubstituted C -6 alkyl, C(0)R 8 or hydroxyl
  • R 5 is hydrogen, halogen, substituted or unsubstituted Ci-e alkyl, C(0)R 8 or hydroxyl;
  • R 6 is hydrogen, halogen, substituted or unsubstituted C -6 alkyl, C(0)R 8 or hydroxyl;
  • R 7 is hydrogen, substituted or unsubstituted Ci -6 alkyl
  • R 8 is OR 9 , substituted or unsubstituted Ci -6 alkyl
  • R 9 is hydrogen, substituted or unsubstituted Ci -6 alkyl
  • a is 1 , 2 or 3.
  • the invention provides a compound having Formula II, wherein:
  • R 1 is substituted or unsubstituted aryl
  • R 2 is substituted or unsubstituted Ci -8 alkyl
  • R 3 is hydrogen
  • R 4 is hydrogen
  • R 5 is hydrogen
  • R 6 is hydrogen
  • R 7 is hydrogen
  • a 1 .
  • the invention provides a compound having Formula II, wherein: R 1 is substituted or unsubstituted aryl;
  • R 2 is methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, iso- pentyl, neo-pentyl, hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3- dimethylbutyl;
  • R 3 is hydrogen
  • R 6 is hydrogen
  • R 7 is hydrogen
  • a 1 .
  • alkyl refers to saturated, monovalent or divalent hydrocarbon moieties having linear or branched moieties or combinations thereof and containing 1 to 8 carbon atoms, such as methyl, ethyl, propyl, iso-propyl, butyl, iso- butyl, sec-butyl, tert-butyl, pentyl, iso-pentyl, neo-pentyl, hexyl, 2-methylpentyl, 3- methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl.
  • One methylene (-CH 2 -) group, of the alkyl can be replaced by oxygen, sulfur, sulfoxide, nitrogen, carbonyl, carboxyl, sulfonyl, or by a divalent C 3 -6 cycloalkyl.
  • Alkyl groups can be substituted by, but not limited to halogen, hydroxyl, cycloalkyl, amino, non-aromatic heterocycles, carboxylic acid, phosphonic acid groups, sulphonic acid groups, phosphoric acid.
  • cycloalkyl refers to a monovalent or divalent group of 5 to 8 carbon atoms derived from a saturated cyclic hydrocarbon. Cycloalkyl groups can be monocyclic or polycyclic. Cycloalkyl can be substituted by, but not limited to d. 8 alkyl groups or halogens.
  • cycloalkenyl refers to a monovalent or divalent group of 5 to 8 carbon atoms derived from a saturated cycloalkyl having one double bond. Cycloalkenyl groups can be monocyclic or polycyclic. Cycloalkenyl groups can be substituted by, but not limited to Ci -8 alkyl groups or halogens.
  • halogen refers to an atom of chlorine, bromine, fluorine, iodine.
  • heterocycle refers to a 3 to 10 membered ring, which can be aromatic or non-aromatic, saturated or non-saturated, containing at least one heteroatom selected form O or N or S or combinations of at least two thereof, interrupting the carbocyclic ring structure.
  • the heterocyclic ring can be saturated or non-saturated.
  • Heterocycles can be monocyclic or polycyclic. Heterocyclic ring moieties can be substituted by, but not limited to hydroxyl, C 1-8 alkyl or halogens.
  • aryl refers to an organic moiety derived from an aromatic hydrocarbon consisting of a ring containing 6 to 10 carbon atoms by removal of one hydrogen, which can be substituted by but not limited to halogen atoms or C-i-s alkyl groups.
  • hydroxyl as used herein, represents a group of formula "-OH”.
  • carbonyl as used herein, represents a group of formula "-C(O)”.
  • carboxyl as used herein, represents a group of formula "-C(0)O”.
  • sulfonyl as used herein, represents a group of formula "-S0 2 ".
  • phosphonic acid as used herein, represents a group of formula "- P(0)(OH) 2 ".
  • phosphoric acid as used herein, represents a group of formula "- (0)P(0)(OH) 2 ".
  • sulphonic acid as used herein, represents a group of formula "- S(0) 2 OH”.
  • N represents a nitrogen atom
  • stereogenic center in their structure.
  • This stereogenic center may be present in an R or S configuration, said R and S notation is used in correspondence with the rules described in Pure Appli. Chem. (1976), 45, 1 1 -13.
  • pharmaceutically acceptable salts refers to salts or complexes that retain the desired biological activity of the above identified compounds and exhibit minimal or no undesired toxicological effects.
  • pharmaceutically acceptable salts according to the invention include therapeutically active, non-toxic base or acid salt forms, which the compounds of Formula I are able to form.
  • the acid addition salt form of a compound of Formula I that occurs in its free form as a base can be obtained by treating the free base with an appropriate acid such as an inorganic acid, such as for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; or an organic acid such as for example, acetic, hydroxyacetic, propanoic, lactic, pyruvic, malonic, fumaric acid, maleic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, citric, methylsulfonic, ethanesulfonic, benzenesulfonic, formic and the like (Handbook of Pharmaceutical Salts, P. Heinrich Stahl & Camille G. Wermuth (Eds), Verlag Helvetica Chimica Acta- Zurich, 2002, 329-345).
  • an appropriate acid such as an inorganic
  • the base addition salt form of a compound of Formula I that occurs in its acid form can be obtained by treating the acid with an appropriate base such as an inorganic base, for example, sodium hydroxide, magnesium hydroxide, potassium hydroxide, calcium hydroxide, ammonia and the like; or an organic base such as for example, L-Arginine, ethanolamine, betaine, benzathine, morpholine and the like.
  • an appropriate base such as an inorganic base, for example, sodium hydroxide, magnesium hydroxide, potassium hydroxide, calcium hydroxide, ammonia and the like
  • an organic base such as for example, L-Arginine, ethanolamine, betaine, benzathine, morpholine and the like.
  • compositions including at least one compound of the invention in a pharmaceutically acceptable carrier.
  • sphingosine-1 -phosphate receptors there are provided methods for treating disorders associated with modulation of sphingosine-1 -phosphate receptors. Such methods can be performed, for example, by administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of at least one compound of the invention.
  • These compounds are useful for the treatment of mammals, including humans, with a range of conditions and diseases that are alleviated by S1 P modulation: not limited to the treatment of diabetic retinopathy, other retinal degenerative conditions, dry eye, angiogenesis and wounds.
  • S1 P modulators are ocular diseases, such as but not limited to: wet and dry age-related macular degeneration, diabetic retinopathy, angiogenesis inhibition, retinopathy of prematurity, retinal edema, geographic atrophy, glaucomatous optic neuropathy, chorioretinopathy, hypertensive retinopathy, ocular ischemic syndrome, prevention of inflammation-induced fibrosis in the back of the eye, various ocular inflammatory diseases including uveitis, scleritis, keratitis, and retinal vasculitis; or systemic vascular barrier related diseases such as but not limited to: various inflammatory diseases, including acute lung injury, its prevention, sepsis, tumor metastasis, atherosclerosis, pulmonary edemas, and ventilation-induced lung injury; or autoimmune diseases and immunosuppression such as but not limited to: rheumatoid arthritis, Crohn's disease, Graves' disease, inflammatory bowel disease, multiple
  • sphingosine-1 -phosphate receptors there are provided methods for treating disorders associated with modulation of sphingosine-1 -phosphate receptors. Such methods can be performed, for example, by administering to a subject in need thereof a therapeutically effective amount of at least one compound of the invention, or any combination thereof, or pharmaceutically acceptable salts, individual enantiomers, and diastereoisomers thereof.
  • the present invention concerns the use of a compound of Formula I or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of ocular disease, wet and dry age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, retinal edema, geographic atrophy, angiogenesis inhibition, glaucomatous optic neuropathy, chorioretinopathy, hypertensive retinopathy, ocular ischemic syndrome, prevention of inflammation- induced fibrosis in the back of the eye, various ocular inflammatory diseases including uveitis, scleritis, keratitis, and retinal vasculitis; or systemic vascular barrier related diseases , various inflammatory diseases, including acute lung injury, its prevention, sepsis, tumor metastasis, atherosclerosis, pulmonary edemas, and ventilation-induced lung injury; or autoimmune diseases and immunosuppression , rheumatoid arthritis, Crohn's disease, Graves'
  • ischemia/perfusion injury contact hypersensitivity, atopic dermatitis, and organ transplantation; or allergies and other inflammatory diseases , urticaria, bronchial asthma, and other airway inflammations including pulmonary emphysema and chronic obstructive pulmonary diseases; or cardiac protection , ischemia reperfusion injury and atherosclerosis; or wound healing, scar-free healing of wounds from cosmetic skin surgery, ocular surgery, Gl surgery, general surgery, oral injuries, various mechanical, heat and burn injuries, prevention and treatment of photoaging and skin ageing, and prevention of radiation-induced injuries; or bone formation, treatment of osteoporosis and various bone fractures including hip and ankles; or anti-nociceptive activity , visceral pain, pain associated with diabetic neuropathy, rheumatoid arthritis, chronic knee and joint pain, tendonitis, osteoarthritis, neuropathic pains; or central nervous system neuronal activity in Alzheimer's disease, age-related neuronal injuries; or in organ transplant such as
  • the actual amount of the compound to be administered in any given case will be determined by a physician taking into account the relevant circumstances, such as the severity of the condition, the age and weight of the patient, the patient's general physical condition, the cause of the condition, and the route of administration.
  • the patient will be administered the compound orally in any acceptable form, such as a tablet, liquid, capsule, powder and the like, or other routes may be desirable or necessary, particularly if the patient suffers from nausea.
  • routes may include, without exception, transdermal, parenteral, subcutaneous, intranasal, via an implant stent, intrathecal, intravitreal, topical to the eye, back to the eye,
  • compositions including at least one compound of the invention in a pharmaceutically acceptable carrier thereof.
  • pharmaceutically acceptable means the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • compositions of the present invention can be used in the form of a solid, a solution, an emulsion, a dispersion, a patch, a micelle, a liposome, and the like, wherein the resulting composition contains one or more compounds of the present invention, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for enteral or parenteral applications.
  • Invention compounds may be combined, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use.
  • the carriers which can be used include glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form.
  • Invention compounds are included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or disease condition.
  • compositions containing invention compounds may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of a sweetening agent such as sucrose, lactose, or saccharin, flavoring agents such as peppermint, oil of wintergreen or cherry, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets containing invention compounds in admixture with non-toxic pharmaceutically acceptable excipients may also be manufactured by known methods.
  • the excipients used may be, for example, (1 ) inert diluents such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating and disintegrating agents such as corn starch, potato starch or alginic acid; (3) binding agents such as gum tragacanth, corn starch, gelatin or acacia, and (4) lubricating agents such as magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
  • formulations for oral use may be in the form of hard gelatin capsules wherein the invention compounds are mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the invention compounds are mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
  • the pharmaceutical compositions may be in the form of a sterile injectable suspension.
  • This suspension may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1 ,3-butanediol.
  • Sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides, fatty acids (including oleic acid), naturally occurring vegetable oils like sesame oil, coconut oil, peanut oil, cottonseed oil, etc., or synthetic fatty vehicles like ethyl oleate or the like. Buffers, preservatives, antioxidants, and the like can be incorporated as required.
  • compositions containing invention compounds may be in a form suitable for topical use, for example, as oily suspensions, as solutions or suspensions in aqueous liquids or nonaqueous liquids, or as oil-in-water or water-in-oil liquid emulsions.
  • Pharmaceutical compositions may be prepared by combining a therapeutically effective amount of at least one compound according to the present invention, or a pharmaceutically acceptable salt thereof, as an active ingredient with conventional ophthalmically acceptable pharmaceutical excipients and by preparation of unit dosage suitable for topical ocular use.
  • the therapeutically efficient amount typically is between about 0.0001 and about 5% (w/v), preferably about 0.001 to about 2.0% (w/v) in liquid formulations.
  • solutions are prepared using a
  • physiological saline solution as a major vehicle.
  • the pH of such ophthalmic solutions should preferably be maintained between 4.5 and 8.0 with an appropriate buffer system, a neutral pH being preferred but not essential.
  • the formulations may also contain conventional pharmaceutically acceptable preservatives, stabilizers and surfactants.
  • Preferred preservatives that may be used in the pharmaceutical compositions of the present invention include, but are not limited to, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate and phenylmercuric nitrate.
  • a preferred surfactant is, for example, Tween 80.
  • various preferred vehicles may be used in the ophthalmic preparations of the present invention. These vehicles include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose cyclodextrin and purified water.
  • Tonicity adjusters may be added as needed or convenient. They include, but are not limited to, salts, particularly sodium chloride, potassium chloride, mannitol and glycerin, or any other suitable ophthalmically acceptable tonicity adjuster.
  • buffers include acetate buffers, citrate buffers, phosphate buffers and borate buffers. Acids or bases may be used to adjust the pH of these formulations as needed.
  • an ophthalmically acceptable antioxidant for use in the present invention includes, but is not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene.
  • Other excipient components which may be included in the ophthalmic preparations are chelating agents.
  • the preferred chelating agent is edentate disodium, although other chelating agents may also be used in place of or in conjunction with it.
  • the ingredients are usually used in the following amounts:
  • the ophthalmic formulations of the present invention are conveniently packaged in forms suitable for metered application, such as in containers equipped with a dropper, to facilitate application to the eye.
  • Containers suitable for drop wise application are usually made of suitable inert, non-toxic plastic material, and generally contain between about 0.5 and about 15 ml solution.
  • One package may contain one or more unit doses.
  • Especially preservative-free solutions are often formulated in non- resalable containers containing up to about ten, preferably up to about five units doses, where a typical unit dose is from one to about 8 drops, preferably one to about 3 drops.
  • the volume of one drop usually is about 20-35 ⁇ .
  • Invention compounds may also be administered in the form of suppositories for rectal administration of the drug.
  • These compositions may be prepared by mixing the invention compounds with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters of polyethylene glycols, which are solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.
  • the compounds and pharmaceutical compositions described herein are useful as medicaments in mammals, including humans, for treatment of diseases and/or alleviations of conditions which are responsive to treatment by agonists or functional antagonists of sphingosine-1 -phosphate receptors.
  • methods for treating a disorder associated with modulation of sphingosine-1 -phosphate receptors can be performed, for example, by administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of at least one invention compound.
  • the term "therapeutically effective amount” means the amount of the pharmaceutical composition that will elicit the biological or medical response of a subject in need thereof that is being sought by the researcher, veterinarian, medical doctor or other clinician.
  • the subject in need thereof is a mammal.
  • the mammal is human.
  • the present invention concerns also processes for preparing the compounds of Formula I.
  • the compounds of Formula I according to the invention can be prepared analogously to conventional methods as understood by the person skilled in the art of synthetic organic chemistry.
  • the present invention concerns also processes for preparing the compounds of Formula II.
  • the compounds of Formula I I according to the invention can be prepared analogously to conventional methods as understood by the person skilled in the art of synthetic organic chemistry.
  • the compounds of the invention may contain one or more asymmetric centers, such that the compounds may exist in enantiomeric as well as in diastereomeric forms. Unless it is specifically noted otherwise, the scope of the present invention includes all enantiomers, diastereomers and racemic mixtures. Some of the compounds of the invention may form salts with pharmaceutically acceptable acids or bases, and such pharmaceutically acceptable salts of the compounds described herein are also within the scope of the invention.
  • the present invention includes all pharmaceutically acceptable isotopically enriched compounds.
  • Any compound of the invention may contain one or more isotopic atoms enriched or different than the natural ratio such as deuterium 2 H (or D) in place of protium 1 H (or H) or use of 13 C enriched material in place of 12 C and the like. Similar substitutions can be employed for N, O and S.
  • the use of isotopes may assist in analytical as well as therapeutic aspects of the invention. For example, use of deuterium may increase the in vivo half-life by altering the metabolism (rate) of the compounds of the invention.
  • These compounds can be prepared in accord with the preparations described by use of isotopically enriched reagents.
  • Some compounds of this invention can generally be prepared in one step from commercially available literature starting materials.
  • GTP Y S binding was measured in the medium containing (mM) HEPES 25, pH 7.4, MgCI 2 10, NaCI 100, dithitothreitol 0.5, digitonin 0.003%, 0.2 nM GTP Y 35 S, and 5 ⁇ g membrane protein in a volume of 150 ⁇ . Test compounds were included in the concentration range from 0.08 to 5,000 nM unless indicated otherwise.
  • Membranes were incubated with 100 ⁇ 5'-adenylylimmidodiphosphate for 30 min, and subsequently with 10 ⁇ GDP for 10 min on ice. Drug solutions and membrane were mixed, and then reactions were initiated by adding GTP Y 35 S and continued for 30 min at 25 °C. Reaction mixtures were filtered over Whatman GF/B filters under vacuum, and washed three times with 3 mL of ice-cold buffer (HEPES 25, pH7.4, MgCI 2 10 and NaCI 100). Filters were dried and mixed with scintillant, and counted for 35 S activity using a ⁇ -counter. Agonist-induced GTP Y 35 S binding was obtained by subtracting that in the absence of agonist. Binding data were analyzed using a nonlinear regression method. In case of antagonist assay, the reaction mixture contained 10 nM S1 P1 in the presence of test antagonist at concentrations ranging from 0.08 to 5000 nM.
  • Table 4 shows activity potency: S1 P1 receptor from GTP Y 35 S: nM, (EC 50 )

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des dérivés de 1,3,4-oxadiazole représentés par les formules I et II, des procédés pour leur préparation, des compositions pharmaceutiques les contenant et leur utilisation en tant que produits pharmaceutiques servant de modulateurs des récepteurs de la sphingosine-1-phosphate.
PCT/US2014/059765 2014-01-15 2014-10-08 Dérivés de diphénylurée servant de modulateurs des récepteurs des peptides formylés Ceased WO2015108577A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461927618P 2014-01-15 2014-01-15
US201461927607P 2014-01-15 2014-01-15
US61/927,618 2014-01-15
US61/927,607 2014-01-15

Publications (1)

Publication Number Publication Date
WO2015108577A1 true WO2015108577A1 (fr) 2015-07-23

Family

ID=51894187

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/059765 Ceased WO2015108577A1 (fr) 2014-01-15 2014-10-08 Dérivés de diphénylurée servant de modulateurs des récepteurs des peptides formylés

Country Status (1)

Country Link
WO (1) WO2015108577A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371296B2 (en) 2014-11-17 2016-06-21 Allergan, Inc. Bicyclic 1,3,4-oxadiazole derivatives as sphingosine-1-phosphate receptors' modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008029370A1 (fr) * 2006-09-08 2008-03-13 Actelion Pharmaceuticals Ltd Dérivés de pyridin-3-yle en tant qu'agents immunomodulateurs
WO2012012477A1 (fr) * 2010-07-20 2012-01-26 Bristol-Myers Squibb Company Composés 3-phényl-1,2,4-oxadiazole substitués
US20120142663A1 (en) * 2010-12-03 2012-06-07 Allergan, Inc. Novel azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008029370A1 (fr) * 2006-09-08 2008-03-13 Actelion Pharmaceuticals Ltd Dérivés de pyridin-3-yle en tant qu'agents immunomodulateurs
WO2012012477A1 (fr) * 2010-07-20 2012-01-26 Bristol-Myers Squibb Company Composés 3-phényl-1,2,4-oxadiazole substitués
US20120142663A1 (en) * 2010-12-03 2012-06-07 Allergan, Inc. Novel azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Salts", 2002, VERLAG HELVETICA CHIMICA ACTA, pages: 329 - 345
PURE APPLI. CHEM., vol. 45, 1976, pages 11 - 13

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371296B2 (en) 2014-11-17 2016-06-21 Allergan, Inc. Bicyclic 1,3,4-oxadiazole derivatives as sphingosine-1-phosphate receptors' modulators

Similar Documents

Publication Publication Date Title
WO2012142268A1 (fr) Dérivés de méthylazétidines bicycliques phényliques en tant que modulateurs des récepteurs de sphingosine-1 phosphate
WO2012142255A1 (fr) Dérivés de méthylazétidines bicycliques substituées en tant que modulateurs des récepteurs de sphingosine-1 phosphate
WO2012074732A1 (fr) Nouveaux dérivés d'oxadiazole phénylique utilisés comme modulateurs des récepteurs de la sphingosine 1-phosphate (s1p)
WO2014127164A1 (fr) Dihydropyrazoles substitués utilisés en tant que modulateurs des récepteurs de la sphingosine
EP2646114A1 (fr) Nouveaux dérivés d'oxime utilisés comme modulateurs du récepteur de la sphingosine 1-phosphate (s1p)
WO2014078197A1 (fr) Dérivés 2-thio-1,3,4-oxadiazole azétidine comme modulateurs de récepteur de phosphate de sphingosine-1
WO2015073140A1 (fr) Dérivés d'aminoacide de 1,3,4-alcényle oxadiazole en tant que modulateurs des récepteurs de la sphingosine-1-phosphate
US9000016B2 (en) 1,3,4-Oxadiazoles-2-thio derivatives as sphingosine-1 phosphate receptors modulators
US8273776B2 (en) Biphenyl oxadiazole derivatives as sphingosine-1-phosphate receptors modulators
WO2015108577A1 (fr) Dérivés de diphénylurée servant de modulateurs des récepteurs des peptides formylés
US9120784B2 (en) 1,3,4-oxadiazoles-2-thio azetidine derivatives as sphingosine-1 phosphate receptors modulators
US8957051B2 (en) Bicyclic 1, 2, 4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators
US8859598B2 (en) 1, 2, 4-oxadiazoles azetidine derivatives as sphingosine-1 phosphate receptors modulators
WO2014127152A1 (fr) Azétidines de pyrazole substitués utilisés en tant que modulateurs des récepteur de sphingosine
US8846729B2 (en) 2-thio-1,3,4-oxadiazoles azetidine derivatives as sphingosine-1 phosphate receptors modulators
WO2015023837A1 (fr) Dérivés d'aryle utilisés en tant que modulateurs des récepteurs de la sphingosine-1 phosphate
WO2014078208A1 (fr) Dérivés aryl oxadiazole comme modulateurs des récepteurs de la sphingosine 1-phosphate (s1p)
WO2015026922A1 (fr) Dérivés alkylés utilisés en tant que modulateurs des récepteurs de la sphingosine-1 phosphate
WO2014127141A1 (fr) Dérivés de 1h-pyrazol-1,2,4-oxadiazole substitués en tant que modulateurs des récepteurs de la sphingosine
WO2014055916A1 (fr) Dérivés aryl-1,2,4-oxadiazoles substitués utiles pour le traitement, entres autres, de maladies oculaires ou inflammatoires
WO2014127149A1 (fr) Dérivés substitués de 4,5-dihydropyrazole-1,2,4-oxadiazole en tant que modulateurs des récepteurs de la sphingosine
WO2014078206A1 (fr) Dérivés allène comme modulateurs des récepteurs de la sphingosine 1-phosphate (s1p)
WO2014130572A1 (fr) 6-méthoxy-4-amino-n-phényl-2-naphtamides substitués en tant que modulateurs des récepteurs de la sphingosine
WO2015073547A1 (fr) Dérivés de phénoxy azétidine disubstitutés utilisés comme modulateurs du récepteur de la sphingosine 1-phosphate (s1p)
WO2015023839A1 (fr) Dérivés d'arylazétidine en tant que modulateurs de récepteurs de la sphingosine-1-phosphate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14796578

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14796578

Country of ref document: EP

Kind code of ref document: A1